<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337853</url>
  </required_header>
  <id_info>
    <org_study_id>2018-139</org_study_id>
    <nct_id>NCT04337853</nct_id>
  </id_info>
  <brief_title>Radiotherapy of Tongue Cancer Using an Intraoral Stent</brief_title>
  <official_title>Implementation of an Intraoral Stent in Radiotherapy of Tongue Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo Metropolitan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiotherapy of tongue cancer is associated with acute and late morbidity. Use of an
      intraoral stent will provide a larger distance between the tongue and palate and can reduce
      side-effects. The aim of the present study is to confirm that an intraoral stent will give
      lower dose to the palate throughout the treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiotherapy of tongue cancer is associated with acute and late morbidity. Use of an
      intraoral stent will provide a larger distance between the tongue and palate and can reduce
      side-effects. The main objective of the present study is to confirm that the use of an
      intraoral stent will result in lower dose to the palate throughout the treatment period. A
      secondary objective is to measure the reduction in acute mucositis in the palate.

      The intraoral stent used in the present study is available in two sizes, 10 and 20mm
      thickness. The intervention group and control group will consist of approximately five
      patients each. Target coverage will be measured by the minimum dose covering 98% of the
      clinical target volume (D98CTV). Dose to the organs at risk (hard and soft palate) will be
      measured by the mean dose. Data will be collected from the planning computed tomography (CT)
      and daily cone-beam CT (CBCT). Acute mucositis will be scored by Common Terminology Criteria
      for Adverse Events (CTCAE) v3.0.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 9, 2018</start_date>
  <completion_date type="Actual">December 4, 2018</completion_date>
  <primary_completion_date type="Actual">December 4, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in mean dose to the hard palate</measure>
    <time_frame>At the end of radiotherapy (5-6 weeks)</time_frame>
    <description>Mann-Whitney U test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in mean dose to the soft palate</measure>
    <time_frame>At the end of radiotherapy (5-6 weeks)</time_frame>
    <description>Mann-Whitney U test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in acute mucositis in the hard palate</measure>
    <time_frame>At the end of radiotherapy (5-6 weeks)</time_frame>
    <description>CTCAE score in the hard palate. Mann-Whitney U test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in acute mucositis in the soft palate</measure>
    <time_frame>At the end of radiotherapy (5-6 weeks)</time_frame>
    <description>CTCAE score in the hard palate. Mann-Whitney U test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Tongue Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N=5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N=6</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intraoral stent</intervention_name>
    <description>Radiotherapy with intraoral stent</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intraoral stent</intervention_name>
    <description>Radiotherapy without intraoral stent</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with tongue cancer

          -  Curatively intended radiotherapy requiring a total dose of 50-70 Gy

          -  Age &gt;18 years

          -  Performance status, Eastern Cooperative Oncology Group (ECOG) 0-2

        Exclusion Criteria:

        None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einar Dale, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, Department of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 5, 2020</study_first_submitted>
  <study_first_submitted_qc>April 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>April 5, 2020</last_update_submitted>
  <last_update_submitted_qc>April 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Einar Dale</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Head and neck cancer</keyword>
  <keyword>Intraoral stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tongue Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

